In a phase 3 trial of 1360 men with locally advanced prostate cancer, transdermal estradiol was noninferior to LHRH agonists for 3-year metastasis-free survival (87.1% vs 85.9%; HR 0.96), with fewer hot flashes (44% vs 89%) but more gynecomastia (85% vs 42%).
RCTn = 1,360
Langley et al. Transdermal Estradiol Patches in Locally Advanced Prostate Cancer